Literature DB >> 21285250

The adaptor protein AMOT promotes the proliferation of mammary epithelial cells via the prolonged activation of the extracellular signal-regulated kinases.

William P Ranahan1, Zhang Han, Whitney Smith-Kinnaman, Sarah C Nabinger, Brigitte Heller, Britney-Shea Herbert, Rebecca Chan, Clark D Wells.   

Abstract

The asymmetric organization of epithelial cells is a basic counter to cellular proliferation. However, the mechanisms whereby pro-growth pathways are modulated by intracellular factors that control cell shape are not well understood. This study demonstrates that the adaptor protein Amot, in addition to its established role in regulating cellular asymmetry, also promotes extracellular signal-regulated kinase 1 and 2 (ERK1/2)-dependent proliferation of mammary cells. Specifically, expression of Amot80, but not a mutant lacking its polarity protein interaction domain, enhances ERK1/2-dependent proliferation of MCF7 cells. Further, expression of Amot80 induces nontransformed MCF10A cells to overgrow as disorganized cellular aggregates in Matrigel. Conversely, Amot expression is required for proliferation of breast cancer cells in specific microenvironmental contexts that require ERK1/2 signaling. Thus, Amot is proposed to coordinate the dysregulation of cell polarity with the induction of neoplastic growth in mammary cells. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21285250      PMCID: PMC3996846          DOI: 10.1158/0008-5472.CAN-10-1995

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.

Authors:  Olga K Mirzoeva; Debopriya Das; Laura M Heiser; Sanchita Bhattacharya; Doris Siwak; Rina Gendelman; Nora Bayani; Nicholas J Wang; Richard M Neve; Yinghui Guan; Zhi Hu; Zachary Knight; Heidi S Feiler; Philippe Gascard; Bahram Parvin; Paul T Spellman; Kevan M Shokat; Andrew J Wyrobek; Mina J Bissell; Frank McCormick; Wen-Lin Kuo; Gordon B Mills; Joe W Gray; W Michael Korn
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

2.  Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression?

Authors:  Eva A Turley; Mandana Veiseh; Derek C Radisky; Mina J Bissell
Journal:  Nat Clin Pract Oncol       Date:  2008-03-18

Review 3.  Protein scaffolds in MAP kinase signalling.

Authors:  Matthew D Brown; David B Sacks
Journal:  Cell Signal       Date:  2008-12-03       Impact factor: 4.315

4.  Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.

Authors:  Thomas Frogne; Rikke V Benjaminsen; Katrine Sonne-Hansen; Boe S Sorensen; Ebba Nexo; Anne-Vibeke Laenkholm; Louise M Rasmussen; David J Riese; Patricia de Cremoux; Jan Stenvang; Anne E Lykkesfeldt
Journal:  Breast Cancer Res Treat       Date:  2008-04-14       Impact factor: 4.872

5.  Cell-cell contact interactions conditionally determine suppression and selection of the neoplastic phenotype.

Authors:  Harry Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-23       Impact factor: 11.205

6.  Identification of differential gene expression during porcine conceptus rapid trophoblastic elongation and attachment to uterine luminal epithelium.

Authors:  Jason W Ross; Morgan D Ashworth; Daniel R Stein; Oliver P Couture; Christopher K Tuggle; Rodney D Geisert
Journal:  Physiol Genomics       Date:  2008-11-25       Impact factor: 3.107

7.  Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab.

Authors:  M Pickl; C H Ries
Journal:  Oncogene       Date:  2008-11-03       Impact factor: 9.867

8.  Ras subcellular localization defines extracellular signal-regulated kinase 1 and 2 substrate specificity through distinct utilization of scaffold proteins.

Authors:  Berta Casar; Imanol Arozarena; Victoria Sanz-Moreno; Adán Pinto; Lorena Agudo-Ibáñez; Richard Marais; Robert E Lewis; María T Berciano; Piero Crespo
Journal:  Mol Cell Biol       Date:  2008-12-29       Impact factor: 4.272

9.  Phosphorylation networks regulating JNK activity in diverse genetic backgrounds.

Authors:  Chris Bakal; Rune Linding; Flora Llense; Elleard Heffern; Enrique Martin-Blanco; Tony Pawson; Norbert Perrimon
Journal:  Science       Date:  2008-10-17       Impact factor: 47.728

Review 10.  Epithelial cell surface polarity: the early steps.

Authors:  Lene N Nejsum; W James Nelson
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more
  21 in total

1.  Phosphorylation of angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration, and angiogenesis.

Authors:  Xiaoming Dai; Peilu She; Fangtao Chi; Ying Feng; Huan Liu; Daqing Jin; Yiqiang Zhao; Xiaocan Guo; Dandan Jiang; Kun-Liang Guan; Tao P Zhong; Bin Zhao
Journal:  J Biol Chem       Date:  2013-10-08       Impact factor: 5.157

2.  The Amotl2 gene inhibits Wnt/β-catenin signaling and regulates embryonic development in zebrafish.

Authors:  Zhiqiang Li; Yeqi Wang; Min Zhang; Pengfei Xu; Huizhe Huang; Di Wu; Anming Meng
Journal:  J Biol Chem       Date:  2012-02-23       Impact factor: 5.157

3.  LKB1 tumor suppressor regulates AMP kinase/mTOR-independent cell growth and proliferation via the phosphorylation of Yap.

Authors:  H B Nguyen; J T Babcock; C D Wells; L A Quilliam
Journal:  Oncogene       Date:  2012-10-01       Impact factor: 9.867

4.  Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression.

Authors:  Y-L Hsu; J-Y Hung; S-H Chou; M-S Huang; M-J Tsai; Y-S Lin; S-Y Chiang; Y-W Ho; C-Y Wu; P-L Kuo
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

5.  Reorganization of Ternary Lipid Mixtures of Nonphosphorylated Phosphatidylinositol Interacting with Angiomotin.

Authors:  Ann C Kimble-Hill; Horia I Petrache; Soenke Seifert; Millicent A Firestone
Journal:  J Phys Chem B       Date:  2018-08-27       Impact factor: 2.991

6.  Apatinib suppresses breast cancer cells proliferation and invasion via angiomotin inhibition.

Authors:  Haige Zhang; Jing Sun; Wencui Ju; Bin Li; Yunfeng Lou; Guoqiang Zhang; Gaofeng Liang; Xiaoyong Luo
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

7.  Angiomotin is a novel component of cadherin-11/β-catenin/p120 complex and is critical for cadherin-11-mediated cell migration.

Authors:  Angelica Ortiz; Yu-Chen Lee; Guoyu Yu; Hsuan-Chen Liu; Song-Chang Lin; Melmet Asim Bilen; Hyojin Cho; Li-Yuan Yu-Lee; Sue-Hwa Lin
Journal:  FASEB J       Date:  2014-12-02       Impact factor: 5.191

Review 8.  The Angiomotins--from discovery to function.

Authors:  Susana Moleirinho; William Guerrant; Joseph L Kissil
Journal:  FEBS Lett       Date:  2014-02-15       Impact factor: 4.124

9.  Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.

Authors:  Jacob J Adler; Derrick E Johnson; Brigitte L Heller; Lauren R Bringman; William P Ranahan; Michael D Conwell; Yang Sun; Andy Hudmon; Clark D Wells
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-07       Impact factor: 11.205

10.  Amot130 adapts atrophin-1 interacting protein 4 to inhibit yes-associated protein signaling and cell growth.

Authors:  Jacob J Adler; Brigitte L Heller; Lauren R Bringman; William P Ranahan; Ross R Cocklin; Mark G Goebl; Misook Oh; Hyun-Suk Lim; Robert J Ingham; Clark D Wells
Journal:  J Biol Chem       Date:  2013-04-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.